No tirzepatide tablet or capsule is approved or clinically validated in the United States. In the United States, every current tirzepatide label is for an injection under the skin. There is no approved tirzepatide tablet or capsule, and no validated compounded pill. If a website calls something "oral tirzepatide," the name is doing more work than the evidence.
Real GLP-1 pills do exist. GLP-1 is a gut-hormone signal involved in appetite and blood sugar. Those pills contain semaglutide or orforglipron, not tirzepatide. That difference matters.
Why tirzepatide pills aren't available
Tirzepatide is a peptide, a short chain of amino acids. More specifically, it has 39 amino acids and copies two gut-hormone signals called GIP and GLP-1. The paper that first described the molecule explains that dual action and its engineered structure (Coskun et al., Molecular Metabolism, 2018).
The digestive system is built to break chains like this into smaller pieces. Even if some intact tirzepatide survived stomach acid and enzymes, it would still have trouble crossing the gut wall and reaching the bloodstream in a reliable amount. An injection goes around those barriers.
The current Mounjaro prescribing information and Zepbound prescribing information, both revised in August 2026, list tirzepatide as an injection. Neither label includes an oral form. Tirzepatide injections explains what the established route involves.
Compounding does not solve the absorption problem by itself. Putting tirzepatide into a capsule would change the container, not establish that a dependable amount reaches the blood. No published human trial has established an oral tirzepatide formulation.
What the real GLP-1 pills are
Three branded pill options can create confusion because they appear in the same conversations as tirzepatide. None contains tirzepatide.
| Pill | Active medicine | What makes it different | Main U.S. use |
|---|---|---|---|
| Rybelsus | Semaglutide | Peptide paired with an absorption helper | Type 2 diabetes and cardiovascular risk reduction in certain adults with diabetes |
| Wegovy tablet | Semaglutide | Peptide paired with an absorption helper | Weight management and cardiovascular risk reduction in eligible adults |
| Foundayo | Orforglipron | Small molecule, not a peptide | Weight management in eligible adults |
Oral semaglutide is a useful lesson in how hard peptide pills are to make. Rybelsus and Wegovy tablets contain SNAC, an absorption helper that protects semaglutide locally and helps it cross the stomach lining. The current Rybelsus label reports that roughly 0.4% to 2% reaches the bloodstream, depending on the formulation. A carefully engineered tablet can work even when only a small share gets through. A plain tirzepatide capsule has no comparable evidence.
Clinical testing is what separates a real dosage form from a hopeful idea. In OASIS 1, a 2023 trial of 667 adults without diabetes, oral semaglutide was associated with an average weight change of 15.1% at 68 weeks, compared with 2.4% for placebo (Knop et al., The Lancet, 2023). That study tested semaglutide, not tirzepatide. The oral semaglutide guide covers that medicine on its own terms.
As of September 6, 2026, the day this article was written, these medicines were not tirzepatide: the FDA had approved the Wegovy tablet on December 22, 2025 and Foundayo on April 1, 2026. On August 10, 2026, the UK's MHRA authorized Foundayo for weight management and type 2 diabetes, making the UK the first country in Europe to do so. The same check found one early development worth watching: Australia's trial registry lists ACTRN12626000224325, a single-dose study comparing an experimental oral tirzepatide tablet with injected Mounjaro in healthy adults. It posts no results, so it does not create an available or validated tirzepatide pill.
Foundayo is easier to absorb because orforglipron is a small molecule, not a peptide. In ATTAIN-1, a 2025 trial of 3,127 adults with obesity and no diabetes, average weight change at 72 weeks was 11.2% with the highest studied dose and 2.1% with placebo (Wharton et al., New England Journal of Medicine, 2025). It was not a head-to-head trial against tirzepatide, so those figures do not show that one medicine is better than the other.
A pill isn't automatically the easier choice
The practical tradeoff is daily versus weekly, not simply pill versus needle. Tirzepatide is given weekly. The oral GLP-1 options are taken daily. Rybelsus and Wegovy tablets also have timing rules around food, water, and other medicines, while the Foundayo label does not require an empty stomach.
The familiar GLP-1 stomach effects do not disappear with a tablet. Nausea, diarrhea, vomiting, constipation, and abdominal discomfort appear across the labels. A pill may remove needle anxiety, but it can add a daily routine and its own interaction questions.
There is also no dose-for-dose conversion among these medicines. They are different molecules, studied in different amounts, with different labels. A prescriber has to choose the medicine and route before thinking about a dose. GLP-1 pills versus injections gives the broader route comparison.
Where compounded tirzepatide fits
A compounded tirzepatide prescription is not an oral workaround. Through Promise, tirzepatide is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved.
A licensed provider may still prescribe a compounded formulation; that decision is between the patient and doctor. Compounding can meet an individual prescription, but it does not turn tirzepatide into a proven tablet or make the preparation the same as Mounjaro or Zepbound. The compounded tirzepatide explainer goes deeper into that distinction.
What to ask when the shot is the problem
If avoiding a needle is the real priority, that is useful information for a medical visit. The next question is which pill fits the actual goal: blood-sugar management, weight management, or both. Rybelsus, Wegovy tablets, and Foundayo do not have interchangeable uses.
A careful discussion also covers food-timing rules, other medicines, pregnancy plans, past pancreatitis or gallbladder disease, severe stomach-emptying problems, and a personal or family history of medullary thyroid cancer. These details can change which options make sense.
At Promise, a licensed provider reviews every request, and not everyone qualifies. The clearest starting point is the exact product name rather than the phrase "tirzepatide pill." That gives the provider something real to evaluate and keeps an injection medicine from being mistaken for a tablet.